Skip to search formSkip to main contentSkip to account menu

ruboxistaurin

Known as: 13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione, ruboxistaurin [Chemical/Ingredient] 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (3)

ArxxantLY 333531ruboxistaurin mesilate hydrate

Broader (3)

Enzyme InhibitorsIndolesMaleimides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Quality of Life and Objective Measures of Diabetic Neuropathy in a Prospective Placebo-Controlled Trial of Ruboxistaurin and Topiramate
Background: The Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN) is a validated comprehensive… 
2011
2011
ORAL PROTEIN KINASE C b INHIBITION USING RUBOXISTAURIN
Purpose: To evaluate efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with moderately severe to very… 
2010
2010
A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats.
Review
2006
Review
2006
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
The aim of this manuscript is to report the safety profile of patients treated with ruboxistaurin mesylate (RBX; LY333531), a… 
2006
2006
IN VIVO METABOLISM OF [14C]RUBOXISTAURIN IN DOGS, MICE, AND RATS FOLLOWING ORAL ADMINISTRATION AND THE STRUCTURE DETERMINATION OF ITS METABOLITES BY LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY AND NMR…
Ruboxistaurin (LY333531), a potent and isoform-selective protein kinase C β inhibitor, is currently undergoing clinical trials as… 
Highly Cited
2005
Highly Cited
2005
Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
PURPOSE The purpose of the study was to investigate the effect of orally administered ruboxistaurin (RBX, LY333531), a selective… 
Review
2005
Review
2005
Ruboxistaurin, a Protein Kinase C β Inhibitor, as an Emerging Treatment for Diabetes Microvascular Complications
OBJECTIVE: To review current clinical data regarding the pharmacologic actions of ruboxistaurin (LY333531) mesylate, an inhibitor… 
Review
2005
Review
2005
The next generation of diabetic nephropathy therapies: an update.
Although treatments for diabetic kidney disease are available, many patients still have progressive disease. More effective… 
Review
2005
Review
2005
The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications
The potential for addressing the underlying biological abnormalities in diabetes has eluded most investigators because of the… 
Review
2003
Review
2003
Ruboxistaurin (Eli Lilly).
  • G. Wheeler
  • IDrugs : the investigational drugs journal
  • 2003
  • Corpus ID: 30841442
Eli Lilly & Co is developing the protein kinase C (PKC)-b inhibitor ruboxistaurin, the lead compound from a series of 14-membered… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)